Molecular Profile |
Indication/Tumor Type |
Response Type |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
TP53 R175L
|
colorectal cancer
|
sensitive |
NSC59984
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, treatment with NSC59984 resulted in increased degradation of mutant Tp53 and cell death in a colorectal cancer cell line harboring TP53 R175L in culture (PMID: 26294215).
|
26294215
|
TP53 mutant
|
colorectal cancer
|
predicted - sensitive |
NSC59984
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, NSC59984 treatment resulted in increased Tp53 signaling and cell death in colorectal cancer cell lines harboring TP53 mutations, and inhibited tumor growth in TP53-mutant cell line colorectal cancer xenograft models (PMID: 26294215).
|
26294215
|
TP53 R273H TP53 P309S
|
colorectal cancer
|
sensitive |
NSC59984
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, treatment with NSC59984 induced Tp53 pathway signaling, degradation of mutant Tp53, and cell death in a colorectal cancer cell line harboring TP53 R273H and TP53 P309S in culture (PMID: 26294215).
|
26294215
|
TP53 R175H
|
colorectal cancer
|
sensitive |
NSC59984
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, treatment with NSC59984 resulted in increased degradation of mutant Tp53 and cell death in a colorectal cancer cell line harboring TP53 R175H in culture (PMID: 26294215).
|
26294215
|